ATE399210T1 - Knockout-mutante von vaccinia-virus und verwendung davon - Google Patents

Knockout-mutante von vaccinia-virus und verwendung davon

Info

Publication number
ATE399210T1
ATE399210T1 AT02772289T AT02772289T ATE399210T1 AT E399210 T1 ATE399210 T1 AT E399210T1 AT 02772289 T AT02772289 T AT 02772289T AT 02772289 T AT02772289 T AT 02772289T AT E399210 T1 ATE399210 T1 AT E399210T1
Authority
AT
Austria
Prior art keywords
mva
viruses
mutant
vaccinia virus
present
Prior art date
Application number
AT02772289T
Other languages
English (en)
Inventor
Volker Erfle
Gerd Sutter
Simone Hornemann
Original Assignee
Helmholtz Zentrum Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen filed Critical Helmholtz Zentrum Muenchen
Application granted granted Critical
Publication of ATE399210T1 publication Critical patent/ATE399210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02772289T 2001-09-11 2002-09-11 Knockout-mutante von vaccinia-virus und verwendung davon ATE399210T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10144664A DE10144664B4 (de) 2001-09-11 2001-09-11 Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon

Publications (1)

Publication Number Publication Date
ATE399210T1 true ATE399210T1 (de) 2008-07-15

Family

ID=7698583

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772289T ATE399210T1 (de) 2001-09-11 2002-09-11 Knockout-mutante von vaccinia-virus und verwendung davon

Country Status (9)

Country Link
US (1) US7049145B2 (de)
EP (1) EP1425404B1 (de)
JP (1) JP4406561B2 (de)
AT (1) ATE399210T1 (de)
AU (1) AU2002337083A1 (de)
CA (1) CA2459754C (de)
DE (2) DE10144664B4 (de)
DK (1) DK1425404T3 (de)
WO (1) WO2003023040A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
JP4606838B2 (ja) * 2004-10-20 2011-01-05 富士フイルム株式会社 電子内視鏡装置
EP2023954B1 (de) * 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunologische zusammensetzung
WO2010127115A1 (en) 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors
EP2479272A4 (de) 2010-10-14 2013-11-20 Ajinomoto Kk Verfahren zur herstellung von monatin
FR2969497B1 (fr) * 2010-12-27 2013-06-28 Ceva Sante Animale Composition luminescente comme biomarqueur dans un oeuf aviaire, dispositif et procede correspondants.
JP6569209B2 (ja) * 2014-01-07 2019-09-04 ソニー株式会社 電気的測定用カートリッジ、並びに電気的測定装置及び電気的測定方法
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) * 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
US10736962B2 (en) * 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US10842835B2 (en) 2016-05-25 2020-11-24 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (de) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene
EP4108257A1 (de) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Impfstoff auf mva-basis gegen covid-19, der ein präfusionsstabilisiertes sars-cov-2-s-protein exprimiert
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4316514A1 (de) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Vektoren auf mva-basis und ihre verwendung als impfstoff gegen sars-cov-2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6287570B1 (en) * 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
WO2000073487A1 (en) * 1999-05-27 2000-12-07 Arizona Board Of Regents Novel viral vectors having enhanced effectiveness with dramatically reduced virulence
JP5078617B2 (ja) 2005-09-22 2012-11-21 東京エレクトロン株式会社 選択的プラズマ処理方法およびプラズマ処理装置

Also Published As

Publication number Publication date
EP1425404B1 (de) 2008-06-25
US20050028226A1 (en) 2005-02-03
EP1425404A2 (de) 2004-06-09
DE10144664B4 (de) 2005-06-09
DK1425404T3 (da) 2008-10-06
DE60227268D1 (de) 2008-08-07
AU2002337083A1 (en) 2003-03-24
CA2459754C (en) 2011-05-10
DE10144664A1 (de) 2003-03-27
CA2459754A1 (en) 2003-03-20
JP4406561B2 (ja) 2010-01-27
JP2005502360A (ja) 2005-01-27
WO2003023040A3 (en) 2003-11-27
US7049145B2 (en) 2006-05-23
WO2003023040A2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
DE60227268D1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
DK0702085T3 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
ATE368729T1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie
UA85536C2 (en) Viral antigens
ATE384785T1 (de) Herstellung von viren, virusisolaten, und impfstoffen
DE69332831D1 (de) Rekombinanter schweinepocken-virus
ATE352557T1 (de) Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
UA90098C2 (en) Promoter of vaccinia virus
DE60302848D1 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
ATE362538T1 (de) Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen
DK1594970T3 (da) Fremgangsmåde til generering af rekombinant MVA
DK0831899T3 (da) Rekombinant koppevirus-calicivirus-præparater og anvendelser
HRP20090230T1 (hr) Replikacijski-defektni rna virusi kao cjepiva
ATE504653T1 (de) Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
DE60330795D1 (de) Impfstoff gegen west nile virus
DE60231970D1 (de) Neurovirulenter stamm des west-nile-virus und anwendungen davon
WO2022010860A3 (en) Infectious recombinant vesicular stomatitis virus (rvsv) bearing the spike glycoprotein s of sars-cov-2 and uses thereof
WO2004035808A3 (en) Method for detecting viral inactivating agents
SE0002498D0 (sv) Papillomavirus vaccine
MY146370A (en) Classical swine fever tissue culture live vaccine virus, the tissue culture method of the same and classical swine fever tissue culture live vaccine comprising the same
WO2002078621A3 (en) Replication-competent recombinant virus and methods of use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1425404

Country of ref document: EP